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Abstract
Background: People with cancer are known to be at increased risk of venous thromboembolism (VTE), and this risk is
believed to vary according to cancer type, stage of disease, and treatment modality. Our purpose was to summarise the
existing literature to determine precisely and accurately the absolute risk of VTE in cancer patients, stratified by malignancy
site and background risk of VTE.
Methods and Findings: We searched the Medline and Embase databases from 1 January 1966 to 14 July 2011 to identify
cohort studies comprising people diagnosed with one of eight specified cancer types or where participants were judged to
be representative of all people with cancer. For each included study, the number of patients who developed clinically
apparent VTE, and the total person-years of follow-up were extracted. Incidence rates of VTE were pooled across studies
using the generic inverse variance method. In total, data from 38 individual studies were included. Among average-risk
patients, the overall risk of VTE was estimated to be 13 per 1,000 person-years (95% CI, 7 to 23), with the highest risk among
patients with cancers of the pancreas, brain, and lung. Among patients judged to be at high risk (due to metastatic disease
or receipt of high-risk treatments), the risk of VTE was 68 per 1,000 person-years (95% CI, 48 to 96), with the highest risk
among patients with brain cancer (200 per 1,000 person-years; 95% CI, 162 to 247). Our results need to be considered in
light of high levels of heterogeneity, which exist due to differences in study population, outcome definition, and average
duration of follow-up between studies.
Conclusions: VTE occurs in greater than 1% of cancer patients each year, but this varies widely by cancer type and time
since diagnosis. The absolute VTE risks obtained from this review can aid in clinical decision-making about which people
with cancer should receive anticoagulant prophylaxis and at what times.
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Introduction
Venous thromboembolism (VTE), which includes deep venous
thrombosis and pulmonary embolism, is the third most common
circulatory disorder in Western populations, and in the United
States alone is responsible for an estimated 300,000 deaths
annually [1]. It has been estimated that 20% of these deaths occur
among patients with cancer [2], and that the risk of death is more
than three times higher for cancer patients with VTE than for
those without VTE [3]. Whilst the overall incidence of cancer has
declined over the last two decades, improvements in cancer
survival and changes in the age structure of the population mean
there are now more people in the US living with this illness than
before [4,5]. Furthermore, those cancer treatments such as surgery
and chemotherapy to which this improved survival over time has
been attributed are themselves believed to directly increase VTE
risk [6,7]. Further improvements in cancer survival could therefore
be obtained through more careful targeting of VTE prophylaxis at
both the highest risk patients and at the most appropriate times
within these patients’ disease course [8]. Existing clinical guidelines
recommend primary VTE prophylaxis for cancer patients during
medical and surgical hospitalisations (where not contra-indicated)
[9–12], with recent updates to two sets of guidelines suggesting
that some outpatient chemotherapy patients could also benefit
[11,12]. Further research is clearly required before more intricate
risk stratification can be introduced. Such risk stratification,
however, is difficult in the absence of clear data on the absolute
VTE risk of patients with different cancers over a specifically
defined period of time and how risk varies according to factors
such as stage of disease and treatment modality.
Data from hospital discharge episodes indicate that VTE is
most likely to occur in patients with brain, pancreatic, and
haematological tumours, when data are adjusted for the
prevalence of these cancer types [13–15]. Equivalent evidence
from cohort studies is difficult to interpret because of the absence
of previous efforts to systematically evaluate research data from a
diversity of sources characterising the incidence of VTE among
people with different cancers. The aim of this systematic review
was to use published literature to determine the absolute and
relative risk of symptomatic VTE in cancer patients, stratified by
cancer type and whether patients were considered to be at
particularly high risk of VTE.
Methods
Data Sources and Searches
This review was carried out and reported in accordance with
the PRISMA guidelines for systematic reviews and meta-analyses
(Text S1) [16]. A comprehensive search of the Medline (OVID)
and Embase databases from 1 January 1966 to 14 July 2011 was
carried out to identify published studies that provided a
quantitative estimate of the incidence of VTE in cancer patients,
along with control groups where available (Texts S2 and S3).
Reference lists of appropriate review articles and of the original
retrieved studies were searched to identify studies missed by the
database searches. No original protocol for the review was
produced.
Study Selection
Two authors (F. H. and M. J.G.) reviewed titles, abstracts, and
full text articles, with any discrepancies about study inclusion
resolved by discussion among all three authors. Inclusion and
exclusion of papers was based on the following criteria.
Study design. We included reports from prospective or
retrospective cohort studies. All data from randomised controlled
trial participants were excluded, as these patients are frequently
recruited following strict inclusion and exclusion criteria so are
liable to be unrepresentative of the underlying population of
interest. For instance, very ill patients are usually less likely to be
recruited into trials [17].
Participants. Included studies involved adult patients diag-
nosed with one of the following eight cancer types: breast, lung,
colorectal, prostate, brain, bone, pancreatic, or haematologic
(including all leukaemias, lymphomas, and multiple myeloma).
The first four cancer types were chosen because they are the most
prevalent malignancy types in the United Kingdom [18]. The
other types were selected because previous research suggests that
these types are associated with the highest risk of VTE. Studies
that presented data for all cancer patients (or where the types
under investigation accounted for more than 75% of all cancers
based on UK data [18]) were used to provide our estimate of the
risk of VTE in all cancer patients (averaged across cancer types).
Studies focussing predominantly on patients fitted with indwelling
catheters were not considered. No restrictions were made on the
basis of nationality or on the stage or grade of malignancy. Studies
comprising patients with VTE at baseline were excluded, unless
data were presented separately for patients with and without a
previous VTE. Before the review commenced a decision was made
to exclude any study with fewer than 20 participants, as it was
unlikely that these would produce a sufficient number of people
developing VTE to contribute meaningful information.
Follow-up. To enable the total person-years of observation to
be calculated, we included data from reports that specified one or
more of the following: (i) total person-time of follow-up, (ii) sample
size and mean (or median) follow-up per patient, or (iii) sample size
and cumulative incidence rate. We excluded studies where the
average duration of follow-up was less than 30 d, hence studies
containing only in hospital follow-up following a cancer-related
procedure did not form part of this review.
Outcomes. We included reports that contained information
on the number of patients in the study who developed a primary,
clinically apparent VTE over the course of the study. Usually this
would be a conjugate outcome comprising deep vein thrombosis
and pulmonary embolism. Where only one of these events was
considered, these studies were included but this was clearly stated.
Any multiple or recurrent events were excluded.
Data Extraction and Quality Assessment
Data were extracted independently by two authors (F. H. and
M. J. G.). When multiple publications were available from a single
cohort, we extracted data from the paper that provided
information on the greatest total duration of follow-up for each
cancer type (and overall cancer) in order to maximise information.
We did not formally assess the quality of the studies included in the
review. This was because available assessment tools such as the
Newcastle-Ottawa scale for cohort studies are based on criteria
including ‘‘the selection of control subjects’’ and ‘‘degree of
adjustment for confounders’’ that cannot easily be adapted to
situations where the primary reason for reviewing the paper is to
extract data on incidence. Specific methodological issues—such as
how factors including duration of follow-up and ascertainment of
VTE in the source studies could impact the overall findings from
this review—were considered carefully.
For each study the number of patients who developed VTE and
the total person-years of follow-up were extracted from the study
report. Where the total person-years of follow-up was not explicitly
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stated, this was obtained by multiplying the mean follow-up per
patient by the number of participants (using the median as an
approximation if only this was available). If only the number of
patients and cumulative incidence were provided (defined as the
number of people who developed VTE over a specified time
period following diagnosis/treatment, ignoring the potential for
censoring due to death), then total person-years of follow-up could
be calculated as long as either the median survival or the
percentage of the sample alive at the end of the period under study
was specified. In this instance, the total person-years of follow-up
was estimated assuming an exponential survival function.
Where study reports specified the number of people (and VTE
events) with each cancer type but where average follow-up was
stated only for the cohort as a whole, we felt it was not reasonable
to assume equal follow-up for each cancer type, given the widely
different prognosis (i.e., survival) for different cancers. Two
exceptions were made to this. In one study, the duration of
follow-up for all patients was short (2.4 mo), such that there would
be little opportunity for differential prognosis to impact on average
follow-up times [19]. In the second study, participants were
followed up for a maximum of 2 y, and person-years of follow-up
for each cancer type could be estimated using available data on the
probability of surviving to 2 y for the specified cancer type and
assuming exponential survival [20]. When analyses were repeated
with the exclusion of these two studies, the results did not change
appreciably.
Categorisation of Studies as Average or High Risk
We stratified papers by whether study participants were average
(population-based) risk or high risk based on their underlying risk
of VTE. We defined average-risk populations as those where we
judged that the participants were representative of all patients with
the cancer type under investigation (or overall cancer). High-risk
populations were those where all or the majority of participants
either had high-grade or metastatic disease, or underwent
procedures for treating the underlying malignancy that are
believed to increase thromboembolic risk, including surgery,
radiotherapy, and chemotherapy [6,7]. Decisions on whether to
categorise study populations as average or high risk were made
jointly by all three authors.
Data Synthesis and Analysis
All analyses were carried out using Stata v. 11. For each study,
the natural logarithm of the incidence rate (number new cases/
1,000 person-years) was estimated, along with the standard error
(1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
VTE
p
events) [21]. These were then pooled for each cancer
type assuming random effects using the generic inverse variance
method. This method considers the inverse of the variance of the
effect estimate, i.e., 1/(Standard Error)2, as the weight given to
each study, so studies with more VTE events are given greater
weight than studies with fewer events. Heterogeneity, the variation
between study results, was assessed using the I2 statistic [22].
Usually, where the degree of heterogeneity is large (I2.75%),
subgroup analyses are encouraged to explore the between-study
heterogeneity. However, in the present review we felt the overall
number of studies in each analysis was too small for such an
analysis to be meaningful.
We performed separate analyses for high- and average-risk
populations, as described above, as well as for each cancer type.
Given the somewhat arbitrary judgement involved in categorising
study populations as either high or average risk, we performed an
additional analysis restricting the former group to study popula-
tions that were categorised as high risk on the basis of having
received cancer treatments at baseline. Statistical methods for
pooling incidence rate ratios were not required here because only
one study meeting the inclusion criteria contained a control group
for which both the number of VTE events and person-years of
follow-up were explicitly stated.
Results
Selection of Studies
A total of 7,274 articles were identified via our search strategy,
and the full text was retrieved for 293 articles. Of these, 46 reports
from 38 individual cohorts (studies) were included in the review
[19,20,23–66] (Figure 1). There were six separate papers from a
single cohort from California (one providing incidence rates of
VTE for 15 separate cancer types [33], and five individual reports
focussing on cancers of the lung, breast, bowel, brain, and
leukaemia [24,32,34,45,56]). In a separate study of outpatient
chemotherapy patients [19], a subsequent publication became
available that provided information on a greater number of
patients with respect to overall cancer risk [35]. The original paper
from the Austrian Cancer and Thrombosis Study (CATS) [20] was
used to extract data for overall and haematological malignancies,
whilst data on larger numbers of people with specific solid tumours
were available from two subsequent publications [41,62].
Among the papers excluded at the full text stage, 17 were from
cohorts that were otherwise eligible, except for the absence of
sufficient information in the paper to be able to estimate both the
total person-years of follow-up and number of VTE events [67–
83]. All included studies were identified from the search terms
listed in Texts S2 and S3. A careful investigation of two recent
review articles on this topic did not result in the identification of
any additional studies that met our review criteria [8,84].
Overview of Included Studies
Details of included studies are summarised in Table S1. Of the
38 included studies, 20 were from Europe, 14 from North America
(US and Canada), one contained participants from both the US
and Europe, and three studies were conducted in Asia. One study
using the SEER-Medicare database was restricted to people aged
65 y old and over [39]; the average age (mean or median) of
participants at baseline for all other studies ranged from 47 to
68 y.
Of the 38 cohorts, 31 were categorised as high risk and seven
were categorised as average risk because they were judged to be
representative of all patients with a cancer diagnosis
[30,33,36,40,57,61,64]. Studies were classed as high risk when
follow-up commenced following outpatient chemotherapy (n=9),
surgery (n=8), inpatient hospitalisation (not specifically for
surgery, n=2), or a receipt of a mixture of treatment types
(n=7), or because either all or the majority of patients had
advanced or metastatic cancer at baseline (n=5). Prophylaxis was
administered to either some (.20%) or all of the participants in 11
studies; with this intervention taking the form of either anticoag-
ulant prophylaxis (with or without mechanical methods)
[23,31,47,53,55,58,59], mechanical prophylaxis only [25,27],
aspirin [42], or unspecified prophylaxis [28]. In a further six
studies it was stated explicitly that no patients [20,26,37,38,43,44]
were receiving anticoagulant prophylaxis, and in two further
studies [29,66] there was a small number (,5%) receiving
warfarin or heparin. In all other reports this information was
either not known or not reported.
Overall Risk of VTE
For average-risk studies, incidence rates of VTE ranged from 8
per 1,000 person-years over an average of 27 mo in Denmark [36]
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Figure 1. Flow diagram for study selection.
doi:10.1371/journal.pmed.1001275.g001
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to 26 per 1,000 person-years in the 6 mo following diagnosis in the
Netherlands [30] (pooled incidence rate 12.6 per 1,000 person-
years; 95% CI, 7.0 to 22.6; heterogeneity I2.99%) (Figure 2;
Table S2). The pooled incidence rate from eight studies combining
data from high-risk samples was 68.0 per 1,000 person-years (95%
CI, 48.0 to 96.4; heterogeneity I2 = 93.4%), with average follow-up
durations ranging from 1 mo to 26 mo.
Risk of VTE by Cancer Type
Pooled estimates for all eight cancer types are summarised in
Figures 3–10 and Tables S3, S4, S5, S6, S7, S8, S9, S10. Cancers
of the pancreas (59 per 1,000 person-years) and brain (48 per
1,000 person-years) were associated with the greatest and second
greatest risk of VTE among average-risk patients, whilst their
relative importance was reversed among high-risk groups (brain,
200 per 1,000 person-years; pancreas, 155 per 1,000 person-
years). Prostate cancer was found to be associated with a low risk
of VTE in both average- (8 per 1,000 person-years) and high- (19
per 1,000 person-years) risk studies (Figure 6; Table S6); breast
cancer was associated with the lowest risk of VTE among
average-risk groups (5 per 1,000 person-years), but among those
at high risk of VTE, this rose to 55 per 1,000 person-years
(Figure 3; Table S3). Patients with colorectal, lung, and
haematological malignancies had risks of a similar magnitude to
the rate among all cancer patients. Only two studies from
average-risk populations provided data on bone cancer, and these
provided strikingly different estimates of the VTE risks in these
patients. I2 values ranged from 74.4% to 98.8% when pooling
average-risk studies and from 0.0% to 92.9% when pooling high-
risk studies.
Risk of VTE when Follow-Up Commenced at Cancer
Diagnosis
Figure S1 summarises the pooled estimates of VTE for each
cancer type for all studies where follow-up commenced at the time
of cancer diagnosis regardless of whether the study was classed as
average or high risk in the previous analysis (n=14 cohorts).
Whilst the relative importance of the cancer sites is similar to that
in the average-risk analysis, absolute risks of VTE are usually
higher in this instance (ranging from 7.7 per 1,000 person-years for
breast cancer to 110.1 per 1,000 person-years for pancreatic
cancer).
Risk of VTE following High-Risk Treatments
When the analysis of high-risk groups was restricted to studies of
patients receiving high-risk treatments at baseline (n=26), the risk
of VTE among all cancer patients increased slightly to 72.7 per
1,000 person-years (95% CI, 44.2 to 119.5). For several individual
cancer types there were also small increases in the pooled risk after
making this restriction, the largest of which occurred among
people with colorectal cancer (81.0 per 1,000 person-years; 95%
CI, 46.7 to 141.2; heterogeneity I2 = 40.2%, n=3 studies) and
brain cancer (217.1 per 1,000 person-years; 95% CI, 171.5 to
274.9; heterogeneity I2 = 0.0%, n=4 studies) (data not shown).
Only for lung cancer was the pooled risk reduced slightly after
making this restriction (67.5 per 1,000 person-years; 95% CI, 39.6
to 115.1; heterogeneity I2 = 83.9, n=7 studies).
Further restriction of brain cancer studies to only those where
patients received anticoagulants as prophylaxis around the time of
surgery (n=3 studies) had little effect on the pooled estimate (211.3
per 1,000 person-years; 95% CI, 165.1 to 270.5; heterogeneity
I2 = 0.0%). There were insufficient numbers of studies comprising
patients receiving anticoagulants to perform an equivalent analysis
for other cancer types.
Relative Risk of VTE Compared with the General Population
Just one of the included studies [36] provided a direct
comparison with the risk of VTE in the general population,
whereby five controls were matched to each cancer patient
specifically on birth, sex, and region (Figure 11). Overall, the risk
of VTE was increased 4-fold in cancer patients (incidence rate
ratio = 3.96; 95% CI, 3.68 to 4.27). The relative importance of
individual cancer types reflected those for the absolute VTE risks,
except for a high incidence rate ratio for haematological cancer,
reflecting the lower rate in the mainly younger matched controls
linked to people with this type of cancer.
Discussion
In a pooled analysis of data from 38 study populations, we
estimated the annual incidence rate of VTE to be between 0.5%
and 20% depending on the cancer type and background risk.
Cancers of the brain and pancreas were associated with the highest
risk of VTE both within study populations classed as high risk and
within those classed as average risk. Current guidelines recom-
mend VTE prophylaxis for hospitalised cancer patients and for
selected high-risk ambulatory patients who are receiving systemic
chemotherapy [9–12]. By providing more accurate data on the
absolute risks of VTE in different groups and weighing these
against the bleeding risks entailed with such therapy, fu-
ture updates of these guidelines can incorporate more careful
risk stratification to highlight which patients should receive
prophylaxis.
Our systematic review and meta-analysis has several strengths.
First, this is, to our knowledge, the first occasion that a review of
the literature on this important topic has attempted to quantify
precisely the likelihood of this potentially devastating complica-
tion, taking account of person-time denominators starting from
the time of cancer diagnosis or treatment. Second, we used two
databases to search the available literature, with search terms
refined to ensure maximum sensitivity. This was supplemented by
searches of reference lists and relevant review articles to ensure
no papers were missed. Third, our separation of studies into high-
and average-risk patient groups achieved two important purpos-
es: it helped alleviate in part the problem of heterogeneity
described below, as shown by the relatively lower I2 values for
some of the high-risk cancer analyses, and more importantly, it
allowed us to estimate the risk of VTE specifically in groups of
patients most likely to benefit from anticoagulant intervention.
The results presented in the review can only be generalised to the
cancer types selected for investigation, which were selected on the
basis of their high prevalence in Western countries or because of
Figure 2. Pooled incidence of venous thromboembolism for overall cancer. Natural logarithms of the incidence rate are presented on the x-
axis. Black diamonds indicate the point estimate (VTE incidence) for each individual study. Horizontal lines indicate the 95% confidence interval
surrounding this estimate. Open blue diamonds describe both the point estimate (centre of the diamond) for the pooled VTE incidence for average-
risk, high-risk, and all studies (average- and high-risk together), and the 95% confidence interval for this pooled estimate (width of the diamond).
Blom (2006) indicates data from [30].
doi:10.1371/journal.pmed.1001275.g002
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Figure 3. Pooled incidence of venous thromboembolism for breast cancer. Natural logarithms of the incidence rate are presented on the x-
axis. Symbols as in Figure 2. Blom (2006) indicates data from [30].
doi:10.1371/journal.pmed.1001275.g003
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Figure 4. Pooled incidence of venous thromboembolism for lung cancer. Natural logarithms of the incidence rate are presented on the x-
axis. Symbols as in Figure 2. Blom (2006) indicates data from [30].
doi:10.1371/journal.pmed.1001275.g004
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Figure 5. Pooled incidence of venous thromboembolism for colorectal cancer. Natural logarithms of the incidence rate are presented on
the x-axis. Symbols as in Figure 2. Blom (2006) indicates data from [30].
doi:10.1371/journal.pmed.1001275.g005
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Figure 6. Pooled incidence of venous thromboembolism for prostate cancer. Natural logarithms of the incidence rate are presented on the
x-axis. Symbols as in Figure 2. Blom (2006) indicates data from [30].
doi:10.1371/journal.pmed.1001275.g006
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Figure 7. Pooled incidence of venous thromboembolism for brain cancer. Natural logarithms of the incidence rate are presented on the x-
axis. Symbols as in Figure 2. Blom (2006) indicates data from [30].
doi:10.1371/journal.pmed.1001275.g007
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evidence of a strong association with VTE risk from previous
research that used different study designs from those included
here.
The main limitation of our work was that the decision to pool
results was often hampered by high levels of heterogeneity
occurring among the individual studies. In descriptive epidemio-
logical studies, where a statistic is estimated among a single group
(such as in this review), the potential for heterogeneity is far greater
than for analytic or comparative studies (i.e., when two groups are
compared to calculate a measure of effect such as an odds or risk
ratio). This is because incidence rates are very sensitive to the
choice of study population, plus other factors such as the definition
of the outcome event and the duration of average follow-up,
meaning at least some heterogeneity will be inevitable; other
published meta-analyses of this type also report very high levels of
heterogeneity [85,86]. Despite this, five of our eight high-risk
analyses were accompanied by I2 values less than 85%, within the
informally defined acceptable limit for carrying out meta-analyses
under random effects.
The problem of heterogeneity was more evident when pooling
results from the average-risk populations, where I2 values exceeded
90% in eight of the nine analyses. This was due to a combination
of very large cohort sizes (greatly minimising the level of within-
study variance) and important differences with respect to study
duration between the three cohorts that contributed the most data
(Chew et al. [33], California; Blom et al. [30], Netherlands;
Cronin-Fenton, et al. [36], Denmark). In the Dutch study, which
considered events occurring in the 6 mo following diagnosis, VTE
rates were always highest, followed by the Californian study,
where the authors considered events over a 2-y period following
diagnosis, with the lowest rates occurring in the Danish study,
where average follow-up was usually longer than 2 y. This pattern
would be expected, considering that VTE is most likely to occur
immediately following cancer diagnosis because patients are more
ill and more likely to receive high-risk treatments during the first
6 mo of their illness, as an earlier case-control study has shown
[87]. This would account for the more comparable rates of VTE
between the Dutch and Californian cohorts associated with
cancers of the lung, brain, and pancreas, where, due to the poor
prognosis of these cancer types, the median follow-up of patients
was short and of similar length in both cohorts. Even allowing for
the slightly longer duration of follow-up, rates of VTE were
somewhat lower in the Danish national registry study [36],
noticeably so for some cancers (i.e., brain cancer). It is probable
that rates of VTE were underestimated in this report, partly as a
result of the authors’ only considering VTE events that were
recorded in inpatient hospital records.
Differences in methods of VTE ascertainment could more
generally be an important factor that explains many of the
differences in VTE rates across this review as a whole. However,
our restriction to symptomatic VTE will have alleviated this problem
to some extent. Differences in the study populations with respect to
geographical location and age could also be important sources
heterogeneity. However, within the analysis of each cancer type, the
average ages of the study participants were broadly similar. Overall,
the small number of studies pooled in each analysis precluded us
from carrying out a detailed statistical investigation to evaluate the
relative importance of the different sources of heterogeneity.
Differences in use of anticoagulants by some or all of the
participants in individual studies could further contribute to
heterogeneity in the results. Where information on prophylaxis use
in study participants was available, prophylaxis reflected existing
guidelines, with anticoagulant prophylaxis given to medical
inpatients [23,53] and those undergoing surgical procedures for
either brain [31,58,59], lung [28,47], or prostate [55] tumours. In
recent years, the trend towards shorter inpatient hospital stays and
improved advice in terms of ambulation, in addition to
prophylaxis, might have resulted in lower rates of VTE than in
the past, especially among surgical patients. There were no older
studies (prior to 1997) comprising cancer patients receiving surgery
that met our review criteria, some of which were excluded because
person-years of follow-up could not be calculated from the data
presented in the paper. If older studies had been carried out that
met our review criteria, then our pooled VTE rates (at least in the
high-risk group) would inevitably be higher. Furthermore, two
studies included in this review hypothesized that the reason
surgical patients in their study had risks of VTE similar to those
receiving alternative treatments or no treatment was because these
patients received adequate levels of prophylaxis, thus compensat-
ing for their higher baseline risk [28,60]. In contrast, the majority
of studies where it was explicitly stated that patients did not receive
prophylaxis were those comprising cancer patients receiving
outpatient chemotherapy [37,43,44,66]. In two additional studies
of chemotherapy patients, whilst anticoagulant use among their
sample was not specified, it was mentioned elsewhere in the paper
that thromboprophylaxis was not the current standard of care for
this group [19,46]. Therefore, we believe our results reflect
contemporary risks of VTE that exist among patients not receiving
prophylaxis other than for short spells during hospital admission.
Our review of cohort studies has confirmed findings from
previous studies using alternative study designs that cancers of the
brain and pancreas are associated with the highest risk of VTE,
Figure 8. Pooled incidence of venous thromboembolism for
bone cancer. Natural logarithms of the incidence rate are presented on
the x-axis. Symbols as in Figure 2. Blom (2006) indicates data from [30].
doi:10.1371/journal.pmed.1001275.g008
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Figure 9. Pooled incidence of venous thromboembolism for haematological cancer. Natural logarithms of the incidence rate are presented
on the x-axis. The studies reported by Chew et al. [33] (non-Hodgkin lymphoma) and Ku et al. [45] (leukaemia) were both from the California Cancer
Registry cohort. However, because they included different subsets of patients and were conducted over different time intervals (Chew, 1993–1995, and
Ku, 1993–1999), a decision was made to pool these as separate studies. Symbols as in Figure 2. Blom (2006) indicates data from [30].
doi:10.1371/journal.pmed.1001275.g009
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Figure 10. Pooled incidence of venous thromboembolism for pancreatic cancer. Natural logarithms of the incidence rate are presented on
the x-axis. Blom (2006) indicates data from [30]. Blom (2006a) indicates data from [29].
doi:10.1371/journal.pmed.1001275.g010
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Figure 11. Relative risks of venous thromboembolism in cancer patients compared with in the general population. Results for
selected cancer types obtained from Cronin-Fenton et al. [36]. IRR, incidence rate ratio.
doi:10.1371/journal.pmed.1001275.g011
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but the increase in risk of VTE with haematological malignancy
was less elevated, in contrast with earlier case-control data [87]. Of
course, our focus on absolute risks would tend to downplay the
influence of cancers that occur more commonly in younger
patients, whose background risk of VTE is considerably lower.
One additional finding of note was the very low risk of VTE in
breast cancer among studies classed as average risk. This was in
part due to inclusion of a study that reported a very low VTE rate
of 0.2% a year in a large sample of women who had stage 1 or 2
breast cancer [40]. Finally, of the cancer types considered here,
bone and soft malignancies were the least studied, with no studies
in high-risk populations meeting our review criteria and only two
in average-risk populations, which reported vastly different
estimates of VTE risk [30,36] (7 and 78 per 1,000 person-years).
This highlights a dearth of research on the thromboembolic risk
associated with this cancer type.
Our review highlights clearly that there are groups of patients
who would be more suitable candidates to receive anticoagulant
prophylaxis based on their underlying risk of VTE. Of course, our
classification into ‘‘high’’ and ‘‘average’’ risk was done at the study
rather than at the patient level. Only through primary studies
could precise estimation of risks be stratified according to
characteristics of the patient. Perhaps more important, though,
will be the need to identify the within-person periods of greatest
risk, including the time since diagnosis as discussed above, so that
the timing of any anticoagulant intervention is most efficient.
Whilst identification of the periods of and persons at greatest
risk is crucial, determining the threshold at which prophylaxis
should be administered is beyond the scope of the present work, as
other factors need consideration. One factor relates to the
effectiveness of agents designed to prevent the occurrence of
VTE. Anticoagulant agents, including both unfractionated and
low-molecular-weight heparin and fondaparinux, are effective in
the prevention of VTE, as shown in randomised controlled trials of
acutely ill medical patients [88,89]. Among patients exclusively
with cancer, less clear evidence is available, with the exception of
one trial that reported an 85% reduction in the risk of VTE among
breast cancer patients with low-dose warfarin administration [90].
Another consideration is the bleeding risk known to exist with
anticoagulants, particularly as these risks are believed to be higher
in cancer patients [91,92]. The need to balance the benefit against
the risks of intervention would thus further affect the optimum
threshold for intervening in this patient group.
In conclusion, by reviewing the existing literature we found that
the risk of VTE is high in patients with cancer and varies markedly
with cancer type. We believe that we have produced estimates of
the risks of VTE in eight specific cancer types that are more
accurate than those previously available. Future updates to clinical
guidelines should incorporate estimates of absolute VTE risk
obtained both from this paper and subsequent research, and
should consider the targeting of VTE prophylaxis in the 6-mo
period following cancer diagnosis, where the risk of a new VTE
has been shown to be greatest.
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Editors’ Summary
Background. A venous thrombosis is the medical term for a
blood clot that forms in a vein, often completely blocking the
vessel. The most common type is a deep vein thrombosis of
the lower leg, which apart from causing pain and immobility,
can break off (embolize), flow through the blood stream back
to the heart, get caught in one of the blood vessels supplying
the lungs, and cause a life-threatening pulmonary embolism.
The term venous thromboembolism (VTE) refers to both a
deep venous thrombosis and a pulmonary embolism and is a
common cause of death, responsible for at least 300,000
deaths a year in the United States alone. There are many risk
factors for developing a VTE, including age, immobility, certain
medications, and some conditions, such as cancer: an
estimated 20% of deaths from VTE occur among patients with
cancer, and importantly, cancer patients with VTE have a much
higher risk of death than those who do not have a VTE. The
increased risk of developing a VTE is due to the treatments and
surgery involved in the management of cancer, in addition to
the risks associated with the condition itself.
Why Was This Study Done? Previous studies have
suggested that certain types of cancer, such as brain and
pancreatic cancer, are associated with an increased risk of
developing a VTE, but to date, clinical guidelines recommend
preventative treatment of VTE only for cancer patients
during hospital admissions for medical treatment and
surgery, not for those patients receiving outpatient care. In
this study, the researchers systematically reviewed the
available published evidence to quantify the risks of
developing a VTE in patients with cancer according to the
type of cancer, and to determine whether certain patient
groups are at particularly high risk of developing a VTE.
What Did the Researchers Do and Find? The researchers
used a comprehensive keyword search of two medical
literature databases to identify relevant studies published
between 1966 and 2011. Then they examined these studies
according to certain criteria, such as the type of study and
the type of cancer: the researchers were specifically looking
for cohort studies of adult patients with one of eight cancer
types—breast, lung, colorectal, prostate, brain, bone, pan-
creatic, and hematologic (including all leukemias, lympho-
mas, and multiple myeloma). The selected studies also had
to include follow-up of more than 30 days and VTE
outcomes. Then the researchers categorized selected studies
according to the risk of developing a VTE—the researchers
judged high-risk patients to be those with metastatic disease
or receiving certain types of high-risk treatments, and judged
average-risk patients to be representative of all patients with
a cancer diagnosis. The researchers then pooled all the data
from these studies and did a separate statistical analysis for
high and average risk and for each cancer type.
Using these methods, the researchers identified 7,274
potentially relevant articles, of which 46 reports from 38
individual cohorts met the criteria to be included in their
review. Of the 38 cohorts, the researchers categorized 31 as
high risk and seven as average risk. In the pooled analysis the
researchers found that among average-risk patients, the
overall risk of VTE was 13 per 1,000 person-years, with the
highest risk among patients with cancers of the pancreas,
brain, and lung. Among patients judged to be at high risk,
the researchers found that the risk of VTE was 68 per 1,000
person-years, with the highest risk among patients with
brain cancer (200 per 1,000 person-years).
What Do These Findings Mean? These findings suggest
that the annual incidence rate of VTE in patients with cancer
is between 0.5% and 20%, depending on the cancer type,
background risk, and time since diagnosis. Cancers of the
brain and pancreas have the highest risk of VTE for both
high- and average-risk patient groups. Based on these more
accurate data on the risks of VTE in different groups of
cancer patients, future updates of clinical guidelines can now
include more information about categories of risk to help
guide clinicians when they make decisions about which
patients should receive preventative treatment for VTE and
when they should receive such treatment.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001275.
N Wikipedia gives more information about VTE (note that
Wikipedia is a free online encyclopedia that anyone can edit)
N Information about VTE for patients and health profession-
als is available from the American Cancer Society, the US
National Cancer Institute, and the UK-based thrombosis
charity Lifeblood
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